Agilent NovoCyte Advanteon Flow Cytometer
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), under the Department of Health and Human Services, has issued a Presolicitation for the acquisition of an Agilent NovoCyte Advanteon Flow Cytometer. This benchtop system is crucial for high-parameter cellular analysis, supporting research into gene expression regulation related to diseases like cancer, hearing loss, and diabetes. The acquisition aims to significantly increase experimental throughput and improve research efficiency. Responses are due by June 22, 2026.
Scope of Requirement
The NovoCyte Advanteon Flow Cytometer is sought by the Section on Regulatory Ribonucleic Acids. It is an advanced platform for multicolor flow cytometry, combining flexible hardware configurations with automated data acquisition and analysis. Its primary function is to conduct research on the regulation of gene expression by ribonucleic acid binding proteins and micro ribonucleic acids, which is vital for understanding disease mechanisms and developing new therapeutic approaches.
Contract & Timeline
- Type: Presolicitation
- Set-Aside: None specified
- Product/Service Code: 6640 - Laboratory Equipment And Supplies
- Response Due: June 22, 2026, 1:00 PM ET
- Published: June 10, 2026
- Place of Performance: Bethesda, MD 20892, United States
Additional Notes
This is a presolicitation notice, indicating that a formal solicitation for the Agilent NovoCyte Advanteon Flow Cytometer is anticipated. Interested parties should monitor SAM.gov for the release of the official solicitation and any subsequent amendments.